Compare Coursera Inc (COUR) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs Pfizer Inc — how do they compare? Coursera Inc trades at $5.28 (market cap $1.35B), while Pfizer Inc trades at $27.81 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 118.2× Coursera Inc's market cap, and Pfizer Inc pays a 6.14% dividend while Coursera Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Coursera Inc for 47 Days and Pfizer Inc for 158 Days on average.
| COUR | PFE | |
|---|---|---|
Market Cap | $1.35B | $159.59B |
Volume | 5,442,629 | 30,937,010 |
Sector | Consumer Staples | Health |
52-Week High | $10.73 | $29.02 |
52-Week Low | $4.64 | $23.67 |
Typical Hold Time | 47 Days | 158 Days |
Enterprise Value | $606.18M | $211.09B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.27, up 2.93% with a bearish technical signal despite recent earnings beats. Revenue growth is solid (2025: $758M, 2026: $885M projected) but profitability remains negative with a -15.39% net margin. Analyst consensus is bullish with a $7.40 price target (52.94% buy ratings), while institutional activity shows mixed positioning amid Project Helix AI platform developments.
The stock offers upside potential from AI-driven growth and margin improvements, but faces execution risks on profitability and integration costs. High RSI near 82 suggests overbought conditions, while persistent net losses and competitive pressures in edtech warrant caution for near-term volatility.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
